Risk factors for mortality in patients with mucormycosis

How I treat mucormycosis

(2011) D. P. Kontoyiannis et al.   BLOOD

Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007

(2011) A. Skiada et al.   CLINICAL MICROBIOLOGY AND INFECTION

The Deferasirox–AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial

(2011) Brad Spellberg et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases

(2010) Shmuel Shoham et al.   MEDICAL MYCOLOGY

The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis

(2010) Ashraf S. Ibrahim et al.   MOLECULAR MICROBIOLOGY

Safety and Outcomes of Open-Label Deferasirox Iron Chelation Therapy for Mucormycosis

(2009) B. Spellberg et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Recent Advances in the Management of Mucormycosis: From Bench to Bedside

(2009) Brad Spellberg et al.   CLINICAL INFECTIOUS DISEASES

Zygomycosis in Solid Organ Transplant Recipients: A Prospective, Matched Case‐Control Study to Assess Risks for Disease and Outcome

(2009) Nina Singh et al.   JOURNAL OF INFECTIOUS DISEASES

Combination Polyene‐Caspofungin Treatment of Rhino‐Orbital‐Cerebral Mucormycosis

(2008) Caitlin Reed et al.   CLINICAL INFECTIOUS DISEASES

Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis

(2008) G. Chamilos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA